NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

NuvOx Pharma
Jul 29, 2021
1 min read

Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.

Click here to read more

Recent Posts

See All

NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction

NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction Tucson, AZ – March 4, 2025 - NuvOx...

NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial

Tucson, AZ – January 21,2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency...

NuvOx Announces Two New Publications

NuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine...

Comentários